Surya Pharmaceutical Ltd - Stock Valuation and Financial Performance

Name: Surya Pharmaceutical
Brand: Surya Pharmaceutical

BSE: 532516 | NSE: SURYAPHARM | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Surya Pharmaceutical

Based on:

Data

M-Cap below 100cr DeciZen not available

Surya Pharmaceutical stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.01

Market Cap:

3.2 Cr.

52-wk low:

0.2

52-wk high:

0.2

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Surya Pharmaceutical:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	TTM
ROCE % ⓘ	13.1%	13.6%	16.3%	12.2%	14.4%	14.2%	13.5%	11.8%	-6%	-6.7%	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	162	169	239	283	487	723	1,134	1,600	1,623	60.3	3
Sales YoY Gr.	-	4.3%	41.2%	18.8%	71.7%	48.6%	56.9%	41.1%	1.4%	-96.3%	-
Adj EPS ⓘ	0.6	0.8	1.9	1.6	2.9	4	5.1	5.2	-12	-13.7	12.8
YoY Gr.	-	38.6%	143%	-14.6%	75.6%	40.3%	27%	0.8%	-332.1%	NA	-
BVPS (₹) ⓘ	5.3	6.1	8.1	9.5	12.3	15.9	20.8	26.6	12.2	-2.7	-41
Adj Net Profit ⓘ	6	8.4	21.3	23.7	41.7	58.5	74.2	99.7	-243	-278	259
Cash Flow from Ops. ⓘ	2.4	2.5	24.5	10.5	67.8	-8.1	165	68.9	386	166	-
Debt/CF from Ops. ⓘ	21	26.6	6	18.6	4.7	-61.8	4.3	20.9	4.6	12.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-10.4%	-34.1%	-62.4%	-96.3%
Adj EPS ⓘ	-242.4%	-236.6%	-238.7%	NA
BVPSⓘ	-192.7%	-173.7%	-150.5%	-122%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13	TTM
Return on Equity % ⓘ	12.8	13.3	25.8	20.2	26.3	28.6	27.8	24.2	-63.4	-287.4	-58.4
Op. Profit Mgn % ⓘ	14	17.7	19.7	18.3	17.8	16.6	14.4	16.4	-8.8	-257.6	-1124.1
Net Profit Mgn % ⓘ	3.7	5	8.9	8.4	8.6	8.1	6.5	6.2	-15	-460	9952.8
Debt to Equity ⓘ	0.9	1	1.6	1.4	1.8	2.2	2.4	2.8	7.1	-37	-
Working Cap Days ⓘ	180	218	198	238	227	251	248	271	303	6,544	1,657
Cash Conv. Cycle ⓘ	74	108	110	152	132	123	126	196	251	5,318	-25,923

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Surya Pharmaceutical Ltd.

	Standalone	Consolidated
TTM EPS (₹)	12.8	-15.7
TTM Sales (₹ Cr.)	2.6	90.4
BVPS (₹.) ⓘ	-41	-4.2
Reserves (₹ Cr.) ⓘ	-852	-106
P/BV ⓘ	0.00	-0.04
PE ⓘ	0.01	0.00

From the Market
52 Week Low / High (₹)	0.16 / 0.16
All Time Low / High (₹)	0.15 / 35.59
Market Cap (₹ Cr.)	3.2
Equity (₹ Cr.)	20.3
Face Value (₹)	1
Industry PE ⓘ	47.2

Management X-Ray of Surya Pharmaceutical:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

97.28

96.74

95.78

78.87

71.67

26.18

* Pledged shares as % of Promoter's holding (%)

Valuation of Surya Pharmaceutical

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Surya Pharmaceutical

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13
Sales	162.07	168.98	238.53	283.40	486.51	722.92	1,134.14	1,600.42	1,622.95	60.33
Operating Expenses ⓘ	139.39	139.02	191.63	231.42	399.93	606.38	971.25	1,337.87	1,807.65	232.59
Manufacturing Costs	8.78	7	9.39	9.64	13.12	17.03	26.75	47.37	44.76	6.98
Material Costs	122.90	122.90	171.44	207.56	363.99	550.61	885.94	1,225.03	1,648.79	180.94
Employee Cost	2.06	2.49	2.77	4.41	8.18	12.91	22.68	40.36	40.91	8.85
Other Costs ⓘ	5.64	6.62	8.03	9.81	14.63	25.83	35.89	25.11	73.18	35.83
Operating Profit ⓘ	22.69	29.96	46.90	51.98	86.58	116.54	162.88	262.54	-184.70	-172.26
Operating Profit Margin (%)	14.0%	17.7%	19.7%	18.3%	17.8%	16.1%	14.4%	16.4%	-11.4%	-285.0%
Other Income ⓘ	0.50	0.24	0.48	2.56	5.01	4.76	10.50	3.47	4.63	0.85
Interest ⓘ	9.63	11.70	13.96	16.33	26.06	41.16	62.36	107.75	178.54	206.90
Depreciation ⓘ	4.80	5.57	6.38	7.94	9.36	16.05	20.55	26.55	34.62	62.47
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	-17.93
Profit Before Tax ⓘ	8.75	12.94	27.05	30.27	56.17	64.10	90.46	131.72	-393.22	-458.71
Tax ⓘ	2.73	4.55	5.76	6.58	14.46	7.97	14.40	31.56	-120.07	-156.90
Profit After Tax	6.02	8.39	21.29	23.69	41.71	56.13	76.06	100.16	-273.16	-301.81
PAT Margin (%)	3.7%	5.0%	8.9%	8.4%	8.6%	7.8%	6.7%	6.3%	-16.8%	-500.0%
Adjusted EPS (₹)	0.6	0.8	1.9	1.6	2.9	3.9	5.3	5.2	-13.5	-14.9
Dividend Payout Ratio (%)	0%	0%	0%	0%	3%	3%	3%	3%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13
Equity and Liabilities
Shareholders Fund	56.86	66.72	90.81	138.23	178.50	230.11	303.19	513.38	247.48	-54.33
Share Capital ⓘ	10.47	10.68	11.08	14.47	14.47	14.47	14.47	19.28	20.28	20.28
Reserves ⓘ	46.39	56.04	79.73	123.76	164.03	215.64	288.72	494.11	227.20	-74.61
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	50.92	67.46	147.82	195.56	317.92	500.73	708.11	1,372.50	1,655.67	1,885.22
Long Term Debt	50.92	67.46	147.82	195.56	317.92	500.73	708.11	265.08	219.43	262.81
Short Term Debt	0	0	0	0	0	0	0	1,107.42	1,436.24	1,622.41
Trade Payables	26.57	30.63	29.72	35.95	87.27	177.46	261.81	68.68	46.34	28.24
Others Liabilities ⓘ	13.58	18.41	24.61	23.76	37.19	40.55	113.32	211.26	76.80	-87.21
Total Liabilities ⓘ	147.93	183.22	292.97	393.51	620.89	948.85	1,386.44	2,165.83	2,026.29	1,771.93
Fixed Assets
Gross Block	65.24	75.92	93.37	120.73	210.99	277.61	314.38	515.91	873.93	879.56
Accumulated Depreciation	19.53	25.10	31.47	39.41	48.77	64.77	84.97	111.52	146.05	208.51
Net Fixed Assetsⓘ	45.70	50.83	61.89	81.32	162.23	212.85	229.40	404.39	727.89	671.05
CWIP ⓘ	0	0	31.25	61.25	29.68	87.93	198.58	232.06	7.40	7.66
Investmentsⓘ	0.10	0.68	0.20	0.25	0.25	0.25	5.50	25.81	34.04	15.90
Inventories	43.95	60.36	80.67	133.53	236.90	373.18	657.26	1,040.63	812.25	628.41
Trade Receivables	32.08	44.11	50.32	73.70	83.23	137.31	153.08	290.85	236.21	225
Cash Equivalents	8.29	6.18	43.94	7.48	33.72	8.23	17.91	15.48	9.88	7.23
Others Assetsⓘ	17.80	21.07	24.69	35.98	74.88	129.10	124.71	156.60	198.62	216.66
Total Assets ⓘ	147.93	183.22	292.97	393.51	620.89	948.85	1,386.44	2,165.83	2,026.29	1,771.93

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13
Cash Flow From Operating Activity ⓘ	2.43	2.53	24.49	10.53	67.79	-8.10	165.31	68.93	385.56	165.55
PBT ⓘ	8.75	12.94	27.05	30.27	56.17	64.10	90.46	131.72	-273.16	-301.81
Adjustment ⓘ	14.41	17.55	20.36	22.29	30.96	52.72	73.01	126.03	224.84	268.16
Changes in Working Capital ⓘ	-10.82	-15.27	-6.4	-36.99	-13.52	-109.11	9.9	-172.67	554.59	325.46
Tax Paid ⓘ	-0.28	-0.98	-2.56	-5.04	-5.82	-15.80	-8.06	-16.14	-120.72	-144.19
Cash Flow From Investing Activity ⓘ	-8.84	-11.02	-47.73	-55.19	-54.20	-120.66	-144.32	-245	-149.98	-7.90
Capex	-9.34	-10.69	-48.70	-57.36	-58.69	-124.92	-147.76	-233.59	-123.16	-8.63
Net Investments	0	-0.58	0.48	-0.05	0.43	0	-5.24	-20.32	-8.22	0
Others ⓘ	0.50	0.24	0.48	2.23	4.05	4.27	8.68	8.90	-18.60	0.74
Cash Flow From Financing Activityⓘ	9.40	6.38	61	8.19	8.61	103.26	-11.32	173.64	-241.17	-160.30
Net Proceeds from Shares ⓘ	13.54	4.12	5.07	18.81	0	0	0	121.10	0.44	0
Net Proceeds from Borrowing ⓘ	-4.14	2.25	55.93	5.72	34.67	145.86	52.78	162.47	-75.36	43.39
Interest Paid ⓘ	0	0	0	-16.33	-26.06	-41.16	-62.36	-107.75	-165.85	-203.69
Dividend Paid ⓘ	0	0	0	0	0	-1.44	-1.74	-2.17	-0.66	0
Others ⓘ	0	0	0	0	0	0	0	0	0.25	0
Net Cash Flow ⓘ	2.99	-2.11	37.76	-36.46	22.19	-25.49	9.68	-2.43	-5.60	-2.65

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	Mar'13
Ratios
ROE (%)	13.07	13.92	27.43	20.83	26.45	27.57	28.68	24.59	-71.8	N/A
ROCE (%)	19.09	20.4	21.69	16.19	19.84	17.17	17.57	16.12	-10.84	N/A
Asset Turnover Ratio	1.27	1.09	1.08	0.89	1.01	0.96	0.99	0.92	0.79	0.03
PAT to CFO Conversion(x)	0.4	0.3	1.15	0.44	1.63	-0.14	2.17	0.69	N/A	N/A
Working Capital Days
Receivable Days	61	77	67	74	56	54	46	50	58	1,303
Inventory Days	87	105	100	128	132	148	162	190	205	4,069
Payable Days	84	85	64	58	62	88	90	49	13	75

Surya Pharmaceutical Ltd Stock News

Surya Pharmaceutical Ltd FAQs

What is the share price of Surya Pharmaceutical?

Company share prices are keep on changing according to the market conditions. The closing price of Surya Pharmaceutical on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Surya Pharmaceutical?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Surya Pharmaceutical stood at ₹3.24.

What is the P/E ratio of Surya Pharmaceutical?

The latest P/E ratio of Surya Pharmaceutical as of 01-Jan-1970 05:30 is 0.01.

What is the P/B ratio of Surya Pharmaceutical?

The latest P/B ratio of Surya Pharmaceutical as of 01-Jan-1970 05:30 is 0.00.

What is the 52-week high and low of Surya Pharmaceutical?

The 52-week high of Surya Pharmaceutical is ₹0.16 and the 52-week low is ₹0.16.

What is the TTM revenue of Surya Pharmaceutical?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Surya Pharmaceutical is ₹2.60 ( Cr.) .

About Surya Pharmaceutical Ltd

Surya Pharmaceutical incorporated in 1992, is engaged in manufacturing of active pharmaceutical ingredients (API's), finished drug formulations (FDF's), fine intermediates, herbal products, and mint/menthol derivatives. The company has client based in over 90 countries across the globe.

The company has received ISO 9001-2000 certifications for its quality management. The company is listed on the Bombay Stock Exchange and the National Stock Exchange. The company has employee strength of more than 2000 people. Company offices located at Shanghai, Singapore, Europe and the United States of America (USA).

Company has production capacity of 600 million of capsules and tablets each per annum.

Products

Intermediates- Under this company manufactures Cefuroxime Acid, Cefaclor and many more.

API-Company has annual capacity of 2500MT of API under which it produces Ampicillin Trihydrat, Cloxacillin Sodium, Flucloxacillin Sodium, Cefprozil, Cefpodoxime Proxetil, Bacampicillin Hydrochloride, Oxacillin Sodium, Cefuroxime Axetil and many more.

Menthol- Under this company manufactures Menthol Powder, Menthol Crystals, Menthol Flakes, Essential Oil, Basil Oil, Dementholised Peppermint Oil, Natural Mint Terpenes, CIS-3-Hexenol, Menthones, Mentha Piperita Oil, Spearmint Oil and Menthyl Lactate. Company has annual production capacity of 4500 MT of Menthol Powder, 3600 MT of Menthol Crystals and 2800 MT of Dementholised Pepermint oil.

Herbal Products- Company manufactures products such as Quinine Sulphate, Quinine Hydrochloride, Colchicine, Thiocolchicoside, Raubasine, 5-HTP and 10-DAB III.

Company also conduct contract manufacturing for various companies.

Recent DevelopmentSurya Pharmaceutical plans to establish 500 healthcare and pharma retail stores in the next three years at an investment of Rs.250 crore. By March 2010, company would open 100 stores in the NCR (national capital region).